Investigation of relationships among upper abdominal symptoms, findings of esophagogastroduodenoscopy (EGD) and quality of life (QOL) and comparing study of therapeutic effects of various gastrointestinal drugs on upper abdominal symptoms of patients with functional dyspepsia (FD) or non-errosive reflux disease (NERD) by using questionnaires to evaluate upper abdominal symptoms (GOS) and QOL (SF-8)

INTERVENTION: Subjects with more than 4 points of GOS score at least one item and no organic disease certified by EGD are medicated with any of the following drugs 1) ‐ 4) for 2weeks, and then answer the questionnaires of GOS and SF‐8 at 1 week and 2 week after medication. 1) Rabeprazole (Pariet) 10mg once daily for 2 weeks 2) Famitidine (Gaster) 10mg twice daily for 2 weeks 3) Mosapride (Gasmotin) 5mg three times daily for 2 weeks 4) Teprenone (Selbex) 50 mg three times daily for 2 weeks CONDITION: Functional dyspepsia (FD), Non‐erosive reflux disease (NERD) PRIMARY OUTCOME: Changes in scores of GOS (Global Overrall Sverity) and SF‐8 (iHope International) questionnaires prior to EGD, at 1 week and 2 weeks after medications SECONDARY OUTCOME: 1)Findings of EGD; 2)Urinary anti‐Helicobacter pylori antibody INCLUSION CRITERIA: Subjects who meet the following requirements 1) ‐ 3) with their consents to participate in the present study are selected from the examinees undergoing a work‐up EGD as a part of a mass‐screening program for gastric cancer, who answer questionnaires of GOS and SF‐8 prior to EGD; 1)GOS score show more than 4 points at least one item. 2)No organic disease is certified by EGD. 3)Patients desire to medicate their upper abdominal symptoms.